Jagsonpal Pharmaceuticals Limited — Investor Meet, 04-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Jagsonpal Pharmaceuticals saw Q4 FY26 revenue up 10% YoY to INR 64 Cr, with PAT surging 31% to INR 9 Cr. FY26 revenue grew 7% to INR 287 Cr, and operating profits increased 19% to INR 45 Cr. The company outperformed the Indian Pharma Market (IPM), reporting 12.2% annual growth (vs IPM 7-8%), fueled by Gynaecology and Dermatology. Management aims for 1.5x IPM growth through enhanced MR productivity, brand focus, and new product launches, while exploring inorganic opportunities. The board approved a INR 40 Cr share buyback and a 200% dividend, returning over INR 66 Cr to shareholders. This strategy reflects confidence in strong cash flows (INR 190+ Cr cash, 11-day working capital) and efficient capital deployment.